test

Current Funding Opportunities

NCCN Request for Proposals (RFP): Phase I/II Clinical Trials and Pre-Clinical Trials of Enzalutamide for Endometrial Cancer

The National Comprehensive Cancer Network® (NCCN®) received a research grant from Astellas Pharma, Inc. and Medivation, Inc. (hereafter, “Grantor”) to support NCCN Member Institution faculty for the design and performance of clinical and pre-clinical studies of enzalutamide in the treatment of selected solid tumors. NCCN will serve as the funding organization for these grants that are available only to NCCN investigators.

The original RFP, issued on June 30, 2014, called for studies in all solid tumors. It was well received and three innovative clinical/correlative studies in various tumor types were selected for funding. Funds of $450,000 are still available to support novel preclinical and clinical studies of enzalutamide in patients with endometrial cancer. Pre-clinical laboratory and correlative/translational studies investigating the clinical relevance of AR expression to disease biology and progression or mechanisms of resistance to enzalutamide will also be considered. Clinical trials and preclinical studies involving rational enzalutamide combination approaches will be considered if supported by strong mechanistic rationale.

Consideration will be given to the following highlighted areas of interest:
• Phase II studies in patients with endometrial cancer;
• Rationally justified (e.g. supported by preclinical data), phase I/II studies of novel combinations with other agents;
• Biomarker or pharmacodynamic studies aimed at determining the clinical relevance of AR expression and response to enzalutamide;
• Novel studies that incorporate evaluation of tissue effects of AR targeting (e.g. tumor response, phenotypic changes, etc.);
• Preclinical and translational studies of novel combinations that could provide data for a future clinical study.
Other:
• Mechanistic studies aimed at understanding AR-driven oncogenesis or AR-dependent progression in endometrial cancer;
• Preclinical studies to evaluate/understand immune mediated response and immune modulation by enzalutamide in endometrial cancer;
• Health related quality of life outcome measures are encouraged as part of clinical studies.

All proposals must be submitted electronically using the directions below and are due by 5:00 PM (EDT) on April 27, 2015. No exceptions will be granted.


PhRMA 2015 Research & Hope Awards

The PhRMA Research & Hope Awards is a prestigious honor that recognizes advances made across a critical disease or health condition by individuals or organizations in the biopharmaceutical sector, academia/government, and the provider and patient communities. It is a celebration of the science, achievements to date, the possibilities to come and the vital role played by members of the biomedical research ecosystem in addressing unmet medical needs and public health imperatives.

The 2015 Research & Hope Awards will honor innovators in the area of oncology research and development, including recent advances in prevention or treatment and/or promising projects in development.  Within the “Excellence in Research” categories, honorees may be nominated from across the spectrum of the ecosystem – scientists working in academic research institutions, government agencies and biopharmaceutical companies (domestic and international).  

Selection Timetable 2015

March 23, 2015 Deadline for receipt of nominations to PhRMA
By April 30, 2015 Voting completed by the PhRMA Foundation Scientific Advisory Committee
September 9, 2015 Award presentation in Washington, DC  




Alex's Lemonade Stand Foundation Infrastructure Grants

We understand the expense of labor intensive pediatric clinical trials. The Infrastructure Grant is designed to help an institution build capacity for and maintain a pediatric oncology Phase I and II clinical trials program by providing funding for adequate staffing, patient care, data management, etc.

Application Deadline: April 10, 2015


Yale-CORE Career Development Program in Patient-Centered Outcomes Research

The Yale-CORE Career Development Program in Patient-Centered Outcomes Research (Y-CORE PCOR) is an AHRQ-funded K12 program within the Yale-New Haven Hospital Center for Outcomes Research and Evaluation that is designed to train junior faculty and postdoctoral fellows in patient-centered outcomes research. Y-CORE PCOR will provide training and career development support for 2 scholars who have a clinical or research doctoral degree and are committed to a career in patient-centered outcomes research (PCOR) and comparative effectiveness research (CER).

Requirements

  • Applicants must have earned a clinical or research doctorate, including PhD, ScD, DrPH, MD, DO, DC, ND, DDS, DMD, DNS or equivalent doctoral degree at the time of appointment and demonstrate commitment to conducting CER, applied to PCOR.
  • At the time of the award, applicant must have a “full-time” appointment at Yale University.
  • Applicants must be able to commit a minimum of nine person-months (75% of full-time professional effort) conducting research career development activities associated with this award for a two or three year period. The remaining three months (25% effort) can be divided among other research, clinical, and teaching activities only if these activities are consistent with the goals of the award, i.e., the candidate’s development into an independent investigator.
  • Applicants may request as much as $90,000 for salary support plus associated fringe and as much as $20,000 for research support per year.
  • Applicants must be US citizens or non-citizen nationals, or individuals lawfully admitted for permanent residence. Additional details on citizenship requirements are available in the HHS Grants Policy Statement.

Application deadline: April 1, 2015 by 5:00 pm

Anticipated start date: July 1, 2015

Learn More>>


Bladder Cancer Advocacy Network (BCAN) Young Investigator Awards

The $100,000 grants will cover costs associated with a two-year bladder cancer-specific research proposal. The purpose of this grant is to support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. Investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research. 

Application Deadline: March 4, 2015 


YCC/SCH Grants for Small Projects to Improve Patient Care

Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven are pleased to announce a new program to fund small projects to improve patient care at Smilow Cancer Hospital. Monies for this program have come through our “Closer to Free” fund. Any employee at Smilow Cancer Hospital who develops a small project may apply by submitting an application for review. Projects can range from a patient education program to stress management for staff. In order to be eligible, the employee must be sponsored by a current Cancer Center Member. A listing of active cancer center members is on the web site.

Grant Details

Amount: $2,500 to $5,000 each

Eligibility: Employees of Smilow Cancer Hospital at Yale-New Haven

Sponsorship: Member of Yale Cancer Center

Application: Limited to 3 pages, typed, double spaced; plus budget with justification (3 copies)

- Application sheet: Project Due Date

- Project Description

- Budget

- Budget Justification

Submit to Renee Gaudette: renee.gaudette@yale.edu

For questions, contact Dr. Ruth McCorkle by email: ruth.mccorkle@yale.edu

Application


2015 Sontag Foundation - Early Career Distinguished Scientist Award for Brain Cancer Research 

Career development award supporting early career scientists with inspiring, potential-laden brain cancer proposals. The foundation is highly interested in researchers that may bring new perspectives to bear on the complex questions related to brain cancer. 

Applicant's initial faculty appointment must have been no earlier than March 2012. 

Up to $600,000 over 4 years. 


Application Deadline:  March 19, 2015


Learn More>>

Breast Cancer Alliance (BCA) Announces three Grant Opportunities for 2016

The mission of the BCA is to improve survival rates and quality of life for those impacted by breast cancer through prevention, early detection, treatment and cure. To promote these goals, we invest in innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved.

Exceptional Project Grant:

The Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. The award recognizes creative, unique, and innovative research and is open to applicants at institutions within a 200-mile radius of Greenwich, CT. This is a one-year grant for a total of $100,000. Prior to submission of a formal grant proposal, the BCA requires a one-page Letter of Intent (LOI) and a separate CV. For 2015 grants, those letters will be due on April 2, 2015. The LOI must include the applicant’s name, job title, and institution at the top of the page, and the applicant’s contact information. The document should state the project title and hypothesis, outline the research aim(s) and methods, and include a brief discussion of the project’s potential impact. The CV can be in the NIH biosketch format and should be no more than four pages long. Applicants will be informed by the first week of May 2015 whether they have been invited to proceed with a formal application. Researchers should coordinate with their institutions, as the BCA will accept a maximum of three LOIs per institution.  (Full proposals, if invited, will be due on or before July 24, 2015.)

Please note that the Exceptional Project Grant due date for LOIs selected by the Yale Scholar Award Committee is April 2.

Young Investigator Grants : Note: No limit on the number of submissions per institution.

To encourage a commitment to breast cancer research, the Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant. This grant is open to applicants at institutions within a 200-mile radius of Greenwich, CT. This is a two-year grant for a total of $125,000, with half the grant award being paid out each year.

Applicants for 2016 grants much (i) have held a faculty position for no more than four years following the completion of their training, as of February 1, 2015; (ii) have not been a principal investigator on an NIH R01 or equivalent national/international non-mentored award; and (iii) dedicate at least 50% of their work effort to research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support. Grant applications are due on or before July 24, 2015. An independent External Review Committee reviews and evaluates the applications. Based on their results and subsequent review by the Grants Committee, recommendations will be made to the BCA Board for final approval. Applicants will be notified in mid-December of the decision regarding their proposals. To download an application, click here: 2016-YIG-application For questions about any research grants, please e-mail: researchgrants@breastcanceralliance.org

Education and Outreach Grants:

The Breast Cancer Alliance offers grants to support programs directly related to outreach and case managerial breast cancer services, including education, counseling, and mammograms for the uninsured/underserved. The programs must be located in Connecticut and/or Westchester County, New York. This is a one-year grant.

For 2016 grants, final applications are due on or before July 31, 2015. The Grants Committee of the Breast Cancer Alliance reviews and evaluates each grant proposal. The results of the Grants Committee’s evaluations and subsequent recommendations are presented to the BCA Board for approval. Applicants are notified in mid-December of the decision regarding their proposals. To download the final report form for 2014 grants, click here for the 2014 Final Report

For questions about any education and outreach grants please email: edout@breastcanceralliance.org

Learn More>> 

2015 Taub Foundation Grants Program for MDS Research

Funding up to $600,000 over 3 years.

The Taub Foundation Grants Program for Myelodysplastic Syndromes Research was created to support high-impact, innovative translational research to understand the underlying causes of MDS and to advance its treatment and prevention. The Program specifically focuses on MDS research, exclusive of AML and MPN. Studies focusing on molecular genetics, epigenetics, splicing factors, stem cells, the microenvironment and novel therapeutic targets relevant to MDS are encouraged. The Taub Program supports independent investigators at all stages of their careers. Awards are not restricted to investigators currently working in MDS. Applications from investigators in other fields and collaborative efforts are encouraged.

Application Deadline: March 17, 2015

Learn More >>

2015 New York Stem Cell Foundation - Innovator Awards for Early Career Investigators in Translational Stem Cell Research

Funding up to $1.5 M over 5 years.

NYSCF is soliciting applications from early career investigators for Innovator awards to be used for exploring the basic biology and translational potential of stem cells. The goal of this initiative is to foster bold and innovative scientists with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. In addition to providing funding, NYSCF partners with investigators to advance and translate their research. To be eligible, candidates must be within 5 years of starting a faculty or comparable position on June 1, 2015.

Application Deadline: March 18, 2015

Learn More >>